Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm


Disclosures: M.T.C. and A.C.L. are employees of Celator Pharmaceuticals/Jazz Pharmaceuticals. The other authors declare no competing financial interests.

Contributions: R.B.W. and E.H.E. designed the study, contributed to patient recruitment, participated in data analysis and interpretation, and drafted the manuscript. M.O. performed all statistical analyses and interpreted data. R.B.W., K.F.O. and E.N.M. collected and assembled clinical data. B.L.S., P.S.B., M.E.M.M., P.C.H., and B.C.M. contributed to patient recruitment. M.T.C. and A.C.L. contributed to the conception and design of the study. All authors critically revised the manuscript.